1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BeOne Medicines AG

BeOne Medicines AG

ONC
BeOne Medicines AGUS flagNASDAQ
358.26
USD
-4.42
- -
38.28BMarket Cap
BeOne Medicines AG
ONC
(NASDAQ)

Recent

price

358.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.21
0.25
0.28
0.03
5.23
3.58
7.13
3.7
12.68
13.73
23.55
36.19
48.99
55.28
Revenue per Share
-0.14
-0.35
-1.81
-3
-2.04
-12.15
-15.8
-19.47
-15.71
-19.43
-8.45
-6.12
2.63
5.91
Basic EPS, GAAP
0.07
-0.18
-1.43
-2.85
-1.01
-12.42
-15.13
-18.1
-17.39
-19.06
-16.8
-6.36
7.9
11.81
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.1
-0.13
-0.25
0.68
1.13
2.25
1.2
3.25
4.59
3.23
2.61
2.41
3.03
3.52
Book Value per Share
-0.1
-0.13
-0.25
0.68
1.1
2.18
1.13
3.2
4.52
3.16
2.53
2.31
2.93
3.48
Tangible Book Value per Share
53
53
32
40
46
55
60
83
93
103
104
105
109
111
Basic Weighted Avg Shares
11
13
9
1
238
198
428
309
1,176
1,416
2,459
3,810
5,343
6,129
Sales/Revenue/Turnover
-48.96
-120.88
-643.66
-10,940.19
-41.3
-356.05
-224.16
-536.69
-122.31
-126.4
-49.12
-14.91
8.37
15.06
Operating Margin (%)
2
2
2
2
5
10
19
32
46
66
88
172
142
155
Depreciation Expense
-7
-18
-57
-119
-93
-674
-949
-1,625
-1,458
-2,004
-882
-645
287
656
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
31.17
24.46
Effective Tax Rate (%)
-67.22
-140.22
-647.71
-11,141.78
-39.06
-339.91
-221.53
-526.1
-123.93
-141.52
-35.86
-16.92
5.37
10.7
Profit Margin (%)
-27
34
71
339
764
1,697
862
3,885
6,014
3,739
2,393
1,777
4,405
5,097
Working Capital
15
14
6
17
155
190
267
213
245
244
220
211
1,015
930
LT Debt
-39
26
74
353
684
1,754
978
3,869
6,133
4,383
3,537
3,332
4,361
5,174
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.14
12.18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.63
12.79
Return on Capital (%)
- -
- -
- -
- -
-18.21
-55.94
-70.23
-67.27
-29.15
-38.11
-22.26
-18.77
7.46
14.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
78
137
213
LT Borrowings
962
963
882
LT Finance Leases
53
50
48
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,441
1,445
1,470
Market Capitalization
437,813
429,148
418,827

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,234
6,601
7,216
Cash, Cash Equivalents & STI
4,548
4,792
5,098
Accounts Receivable, Net
865
938
1,056
Inventories
608
682
733
Total Current Liabilities
1,829
1,812
2,119
Payables & Accruals
1,325
1,409
1,564
ST Debt
78
137
213
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
91.21%
7.15%
30.88%
Free Cash Flow
131.43%
-54.5%
-228.56%
Net Income, GAAP
62.24%
-40.04%
-144.5%
Sales/Revenue/Turnover
2,263.27%
94.01%
40.23%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
752
929
1,002
1,128
3,810
2025
1,117
1,315
1,412
1,498
5,343
2026
1,513
1,705
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.41
-1.15
-1.15
-1.43
-6.12
2025
0.01
0.87
1.13
0.6
2.63
2026
2.05
2.12
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Oramed Pharmaceuticals Inc. (ORMP.TA)
Dare Bioscience, Inc. (DARE)
Apollomics, Inc. (APLMW)
Tetra Bio-Pharma Inc. (TBPMF)
Adicet Bio, Inc. (ACET)
CAMP4 Therapeutics Corporation (CAMP)
Business
BeOne Medicines Ltd. (ONC) is a global oncology company that discovers, develops and commercializes innovative cancer treatments spanning hematology and solid tumors; its marketed products include BRUKINSA (zanubrutinib), a second-generation BTK inhibitor approved for chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved for Hodgkin lymphoma, esophageal squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma and small cell lung cancer; and others such as pamiparib and denosumab; the company advances a diverse pipeline of novel therapeutics including sonrotoclax (BCL2 inhibitor), BGB-16673 (BTK degrader), BGB-43395 (CDK4 inhibitor), BG-68501 (CDK2 inhibitor), xaluritamig (STEAP1 x CD3 bispecific), TARLATAMAB-DLLE (CD3 x DLL3 bispecific), antibody-drug conjugates like BG-C9074, bispecific T-cell engagers and PROTACs through internal R&D and collaborations. BeOne Medicines operates in over 45 countries across six continents with major presence in the United States, China, Europe, Australia and Asia; it was founded in 2010 by John V. Oyler and Xiaodong Wang, and is headquartered in Basel, Switzerland following redomiciliation in May 2025 from Cambridge, Massachusetts. Recent developments include a November 2024 rebranding from BeiGene Ltd. with stock ticker change to ONC in January 2025; an August 2025 royalty purchase agreement with Royalty Pharma for up to $950 million on IMDELLTRA (tarlatamab-dlle) sales excluding China, providing $885 million upfront; positive Phase 3 results in August 2025 for sonrotoclax in relapsed/refractory chronic lymphocytic leukemia; European Commission approval in August 2025 for TEVIMBRA as neoadjuvant/adjuvant treatment for non-small cell lung cancer; 41% total revenue growth to $1.4 billion in Q3 2025 driven by 51% increase in global BRUKINSA sales; and pipeline advancements showcased at ASH 2025 including long-term BRUKINSA data and new combinations in B-cell malignancies.

Company News

Company News APIChatGPT

  • zacks.com

    Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

  • businesswire.com

    BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

  • businesswire.com

    BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

  • businesswire.com

    BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

  • zacks.com

    BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

  • zacks.com

    BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

  • businesswire.com

    BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

  • businesswire.com

    BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

  • businesswire.com

    BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

  • defenseworld.net

    Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

  • marketbeat.com

    BeOne Medicines Q2 Earnings Call Highlights

  • seekingalpha.com

    BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript

  • zacks.com

    BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

  • businesswire.com

    BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

  • zacks.com

    Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

  • defenseworld.net

    BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Bought by Arrowstreet Capital Limited Partnership

  • fool.com

    Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

  • businesswire.com

    BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

  • fool.com

    A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position

  • businesswire.com

    BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5